Published in Leukemia on April 13, 2006
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Therapeutic targeting of MLL. Blood (2009) 1.36
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia (2013) 1.00
Genome-wide analysis of transcriptional reprogramming in mouse models of acute myeloid leukaemia. PLoS One (2011) 0.91
The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol (2011) 0.88
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget (2016) 0.75
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr (2017) 0.75
The tripartite motif family identifies cell compartments. EMBO J (2001) 9.64
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
ISWI is an ATP-dependent nucleosome remodeling factor. Mol Cell (1999) 2.68
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34
Telomere regions in Drosophila share complex DNA sequences with pericentric heterochromatin. Cell (1983) 2.29
The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J (1992) 2.18
Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol (2000) 2.06
Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology (2008) 1.98
Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem (1998) 1.86
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia (2009) 1.86
Acf1, the largest subunit of CHRAC, regulates ISWI-induced nucleosome remodelling. EMBO J (2001) 1.81
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol (1998) 1.80
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77
Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem (1991) 1.74
Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71
Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest (1997) 1.70
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia (2011) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Nucleolar function and size in cancer cells. Am J Pathol (1998) 1.66
Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab Invest (1990) 1.64
Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol (2000) 1.59
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br (2002) 1.58
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood (1999) 1.50
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol (2003) 1.46
Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. Am J Clin Nutr (1994) 1.46
Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol (2000) 1.45
[ General postural rehabilitation in musculoskeletal diseases: scientific evidence and clinical indications]. Reumatismo (2007) 1.44
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol (2009) 1.44
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
Absolute alcohol in esophageal vein sclerosis. Gastrointest Endosc (1988) 1.40
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.39
Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia. Hum Gene Ther (1999) 1.39
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem (2000) 1.38
Gene expression profiling in MDS and AML: potential and future avenues. Leukemia (2011) 1.38
Hmg4, a new member of the Hmg1/2 gene family. Genomics (1998) 1.37
Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem (1993) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Structural and functional analysis of a growth-regulated gene, the human calcyclin. J Biol Chem (1987) 1.36
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer (2001) 1.34
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res (2001) 1.33
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer (2007) 1.33
Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol (1993) 1.32
Template-imprinted nanostructured surfaces for protein recognition. Nature (1999) 1.32
Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol (1990) 1.32
Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer (2001) 1.31
Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem (1999) 1.30
Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. J Med Chem (1996) 1.29
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res (1992) 1.29
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Different brain correlates for watching real and virtual hand actions. Neuroimage (2001) 1.28
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
Molecular cloning of a cDNA for a human ADP/ATP carrier which is growth-regulated. J Biol Chem (1987) 1.27
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia (2011) 1.26
Differential response of embryonic and fetal myoblasts to TGF beta: a possible regulatory mechanism of skeletal muscle histogenesis. Development (1994) 1.25
Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res (1991) 1.25
Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene (2000) 1.24
Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer (1999) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Activation of c-myb expression by phytohemagglutinin stimulation in normal human T lymphocytes. Mol Cell Biol (1985) 1.22
Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol (2001) 1.22
A stimulated S6 kinase from rat liver: identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J (1989) 1.22
Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. J Med Virol (1995) 1.22
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem (2000) 1.21
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol (1993) 1.19
Pre-B and B cells in children on leukaemia remission maintenance treatment. Clin Exp Immunol (1979) 1.19
Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. Proc Natl Acad Sci U S A (1996) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Two histone fold proteins, CHRAC-14 and CHRAC-16, are developmentally regulated subunits of chromatin accessibility complex (CHRAC). EMBO J (2000) 1.18
Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents (2001) 1.18
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis (2004) 1.18
Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction. Blood (1991) 1.17
Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene (2007) 1.17
High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol (2002) 1.17
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia (2012) 1.16
Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand (1998) 1.16
Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem (2001) 1.16
Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer (1993) 1.16
N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori (1991) 1.16
Unmasking a growth factor/oncogene-activated S6 phosphorylation cascade. Cell Signal (1989) 1.14
The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci (2001) 1.13